肺癌患者化疗前后血清SIL-2R、SCP活力检测的临床意义

Clinical Significance of Measurement of Changes of Serum SIL-2R and SCP Levels After Chemotherapy in Patients with Lung Cancers

目的:探讨了肺癌患者化疗前后血清SIL-2R和SCP活力的变化。方法:采用酶联免疫法(ELISA)和生化速率比色法测定了32例肺癌患者化疗前后血清SIL-2R和SCP活力的变化,并与30名正常健康人作比较。结果:化疗前血清SIL-2R和SCP活力均非常显著地高于正常人(P<0.01),化疗后6个月复发者血清SIL-2R和SCP活力持续异常,未复发者SIL-2R和SCP活力水平恢复正常。结论:观察肺癌患者免疫功能的变化与患者的病情和预后密切相关。

Objective To study the changes of serum SIL - 2R and SCP levels after chemotherapy in patients with lung cancers. Methods Serum SIL-2R （with ELISA） and SCP （with biochemistry） levels were measured in 32 patients with lung cancers both before and after chemotherapy as well as in 30 controls. Results Before chemotherapy, in the patients, the serum SIL -2R and SCP levels were significantly higher than those in controls （P 〈 0.01 ）. Six months after chemotherapy the patients without recurrence （n = 20） had their SIL-2R and SCP lvels returned to normal but in patients with recurrences （n = 10） the levels were about the same as those before chemotherapy. Conclusion Determination of serum SIL -2R and SCP levels changes could reflect the immunostatus of the patients as well as the progress of diseases and could be of prognostic values.